Roche announced a strategic deal with NVIDIA to build an AI 'factory' aimed at accelerating drug and diagnostic development, positioning the Swiss group to compete with peers investing in large‑scale compute. The collaboration centers on deploying high‑performance NVIDIA hardware and software across Roche’s research and development functions to speed molecular design, imaging analysis and biomarker discovery. Roche framed the initiative as an effort to integrate AI into discovery-to-development workflows and to increase throughput for in‑silico experiments and clinical data processing. The pact follows broader industry moves—such as Eli Lilly’s earlier supercomputing investments—intensifying competition to couple compute scale with bioinformatics and translational pipelines.